Haematology
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      1L CLL

      R/R CLL

      AML

      RESOURCE HUB

      CONTACT

      VENCLEXTA logo
      Unresolved questions in selecting a first-line CLL therapy - A podcast featuring Professor Stephen Opat from Monash Health
      Unresolved questions in selecting a first-line CLL therapy - A podcast featuring Professor Stephen Opat from Monash Health
      Unresolved questions in selecting a first-line CLL therapy - A podcast featuring Professor Stephen Opat from Monash Health

      In this podcast, Prof. Stephen Opat (Monash Health) discusses the role of chemo-immunotherapy in first-line CLL, when BTK inhibitors may be the preferred treatment choice, and the advantages of time-limited therapy versus continuous therapy.

      Disclaimer: Thanks for listening to this Educational podcast, initiated and sponsored by AbbVie Pty Ltd (“AbbVie”). The individual opinions expressed within the podcast may not represent the views of AbbVie. AbbVie does not endorse the use of unregistered products or products outside their registered indications. Please refer to the Australian product information for licensed instructions. For references supporting the discussions in these podcasts please see below. For more information, contact medinfoanz@abbvie.com or call 1800 043 460 in Australia. Podcast ID AU-VENC-240009. February 2024. Copyright AbbVie Pty Ltd, Mascot NSW 2024.

      Contact

      Discover more about how we can help you in your practice.

      Contact Now

      PBS Information

      Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.

      Please review the full Product Information (PI) before prescribing, available below.

      Venclexta PI

      References: 1. Bennett R et al. J Hematol Oncol 2023; 16(1): 72. 2. Malcikova J et al. Blood 2021; 23; 138(25): 267085. 3. Frustaci AM et al. Cancers (Basel) 2023; 15(5): 1504. 4. Mato A et al. EJHaem 2023; 4(1): 13544. 5. Stauder R et al. Ann Oncol 2017; 28(2):218227. 6. Quartermaine C et al. JACC CardioOncol 2023; 5(5): 57090. 7. Al-Sawaf et al. J Clin Oncol 2021; 39(36): 404 60. 8. Thompson MC et al. Blood Adv 2022; 6(15): 455357.

      AU-VENC-240009 Last revised April 2024.